miRNA
Singapore's Mirxes Inks Agreements for Cancer Early Detection Tests in China, Indonesia
Mirxes signed an MOU to scale up manufacturing of its tests in China and expanded an existing commercialization partnership in Indonesia.
The company is hoping to bring a blood-based screening test to the clinic after publishing promising results on its novel 18-RNA signature.
Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split
Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.
Tesis Biosciences to Develop miRNA Biomarkers for mTBI Diagnosis
On the heels of its Genome Explorations acquisition, the company wants to create a biomarker panel to differentiate mild traumatic brain injury from PTSD.
Diagnostics Developer Early is Good Raises $4M in Seed Funding
The company will use the funds to complete clinical trials for its first product, BCDx, a laboratory-developed test for early bladder cancer detection.